Any content you receive is for information purposes only. Always conduct your own research. | *Sponsored | See Why (VNRX) Will Be Topping Our Watchlist Tomorrow Morning—Wednesday, March 18th, 2026. | | March 17, 2026 | Recent developments announced for VolitionRx Limited (NASDAQ: VNRX)—and it could reshape how you're looking at this name. | The company confirms active licensing discussions with approximately 10 of the world's leading diagnostic and liquid biopsy companies, per their February business update. These negotiations span all of Volition's pillars, with additional agreements anticipated during 2026. | Here's what caught my attention: the company's vision is for its technologies to be incorporated into tests used by many people and animals per year, with the platform licensed to large diagnostic companies worldwide. | They're not just talking. Volition already signed two significant human agreements in Q3 2025 with major global partners Werfen and Hologic, both recognized leaders in their specialized fields. | Keep reading to quickly get up to speed on why we're highlighting (VNRX) right now. | Per Grand View Research, the global epigenetics diagnostics market is projected to grow at a robust 15.5% CAGR through 2030. At the center of this expanding space is a company quietly reshaping early cancer detection through simple, affordable blood tests. | VolitionRx Limited (NASDAQ: VNRX) will be topping our watchlist tomorrow morning—Wednesday, March 18, 2026. | The company develops proprietary Nucleosomics™ technology for detecting epigenetic changes from the earliest stages of cancer and sepsis. Its breakthrough Capture-Seq™ platform targets a staggering $23B Total Addressable Market. | Per VolitionRx's investor page, the company now serves close to 100 pharma and diagnostic clients worldwide through its Nu.Q® Discover platform, including many top pharmaceutical companies accelerating dr-ug development across multiple therapeutic areas. | Recent Milestones Worth Watching | Fujifilm Automation Breakthrough: Over 1,700 Japanese veterinary hospitals registered with approximately 7M pet dogs in that market, per the March 6 press release. $23B TAM Capture-Seq™: Manuscript submitted for peer review showcasing novel cancer detection method with potential for accurate, low-cost tests across a wide range of cancers, per company update. French Reimbursement On Track: Lung cancer submission underway with Hospices Civils de Lyon, France's second largest university hospital system—routine clinical use expected by Q4 2026. Government-Backed $7.3M Sepsis Program: Nu.Q® NETs included in France's DETECSEPS program providing real-world interventional evaluation for early detection of sepsis. Feline Cancer Breakthrough: Achieved 100% specificity and over 80% sensitivity—unlocking potential $5M milestone payment upon peer-reviewed publication and potentially doubling the veterinary TAM.
| 5 Reasons (VNRX) Tops Our Watchlist | Massive TAM Exposure: Combined addressable markets exceed $27B across Capture-Seq™ cancer detection ($23B), Nu.Q® NETs diagnostics ($3.8B), and veterinary pillars ($1B+). Multi-B Dollar Licensing Momentum: Active discussions with approximately 10 global diagnostic leaders across all pillars, with deals already signed with Werfen and Hologic in 2025. First Clinical Use Imminent: Tests expected to be used in 2026 for both cancer and sepsis in real-world hospital settings—diseases that together account for approximately one-third of deaths worldwide. Global Commercial Partnerships: Strategic deals span major international companies across 20+ countries, including the U.S., Japan, France, and the EU. Recent Funding Secured: The company secured $2.0M in funding in January 2026, providing additional runway as key commercialization milestones approach.
| Per Grand View Research, non-oncology applications project the fastest 16.5% CAGR through 2030, while Asia Pacific anticipates 16.9% growth driven by rising R&D and increasing cancer incidence. | Pull up VNRX Before Tomorrow Morning… | Here's what stands out: a company trading at around $25.5M market cap with $27B+ in combined TAMs, 10 active licensing discussions with global diagnostic giants, first clinical use imminent, and momentum building across every pillar. | We will have all eyes on (VNRX) tomorrow morning—Wednesday, March 18th, 2026. | | Sincerely, | Dean Knightly
Editor, Trading Ideas | | Sources: | | | TradingIdeas.app ("TradingIdeas" or "TI" ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and TI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile TI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. | Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 03/17/2026 and ending on 03/18/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, Goldwyn Media LLC has paid TD Media LLC fifty thousand USD ("Funds"). To date, including under the previously described agreement, TD Media LLC has been paid three hundred thirty three thousand USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. | Neither TD Media LLC and their member own shares of (VNRX:US). | Please see important disclosure information here: https://tradingideas.app/disclosure/vnrx-0JYV9/#details |
|
